GlaxoSmithKline plc (the ' Company ')
Transaction notification
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Ms V Whyte |
|||
b) |
Position/status |
Company Secretary |
|||
c) |
Initial notification/ amendment |
Initial Notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Descriptionofthe financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b) |
Nature ofthe transaction |
Transfer of 10,720 Ordinary Shares between accounts for nil consideration.
|
|||
c) |
Price(s)and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£0.00 |
10,720 |
|
||
|
|
|
|
||
d) |
Aggregated information |
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date ofthe transaction |
2020-02-20 |
|||
f) |
Placeofthe transaction
|
N/A |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Ms V Whyte |
|||
b) |
Position/status |
Company Secretary |
|||
c) |
Initial notification/ amendment |
Initial Notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Descriptionofthe financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b) |
Nature ofthe transaction |
Transfer of 10,838 Ordinary Shares to spouse for nil consideration.
|
|||
c) |
Price(s)and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£0.00 |
10,838 |
|
||
|
|
|
|
||
d) |
Aggregated information |
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date ofthe transaction |
2020-02-20 |
|||
f) |
Placeofthe transaction
|
N/A |
|
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Mr I Whyte |
|||
b) |
Position/status |
PCA of Ms V Whyte (Company Secretary) |
|||
c) |
Initial notification/ amendment |
Initial Notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Descriptionofthe financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b) |
Nature ofthe transaction |
Receipt of 10,838 Ordinary Shares from spouse for nil consideration. |
|||
c) |
Price(s)and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£0.00 |
10,838 |
|
||
|
|
|
|
||
d) |
Aggregated information |
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date ofthe transaction |
2020-02-20 |
|||
f) |
Placeofthe transaction
|
N/A |